Cell Surface Markers: US, Europe (France, Germany, Italy, Spain, UK), Japan--Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities
The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next ten years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.
Abbott
Agilent Technologies
Beckman Coulter/Danaher
Becton Dickinson
BioRad
CellaVision
Horiba
Iris Diagnostics/Danaher
Nihon Kohden
OrthoClinical Diagnostics
Roche
Siemens
Sysmex
Agilent Technologies
Beckman Coulter/Danaher
Becton Dickinson
BioRad
CellaVision
Horiba
Iris Diagnostics/Danaher
Nihon Kohden
OrthoClinical Diagnostics
Roche
Siemens
Sysmex
